Introduction
============

Acute pulmonary embolism (APE) is a prevalent disease (incidence, 100--200/100,000 inhabitants/yr) with a high mortality rate (17.4% for 90-day mortality rate in unselected population).[@b1-tcrm-12-1023] Despite advances in treatment and diagnosis, the antemortem diagnosis of fatal PE has not changed markedly for a long time, remaining stable at approximately 30%.[@b2-tcrm-12-1023] Clinical presentation and the period from onset of symptoms to presentation vary among patients, depending on a number of factors.[@b3-tcrm-12-1023] The classical symptoms of APE include chest pain, dyspnea, and hemoptysis. Syncope is an atypical symptom of APE and has a reported prevalence of approximately 10% as the initial presenting sign.[@b4-tcrm-12-1023]--[@b7-tcrm-12-1023] There are conflicting data concerning syncope and the prognosis of APE. In earlier studies, the presence of a syncopal episode on presentation of APE was reported to be associated with a high risk of mortality.[@b4-tcrm-12-1023],[@b8-tcrm-12-1023] However, this was not confirmed in later studies.[@b6-tcrm-12-1023],[@b9-tcrm-12-1023]--[@b11-tcrm-12-1023] Conversely, one paper also suggested that syncope was associated with good prognosis.[@b12-tcrm-12-1023] It is important to determine whether syncope is associated with poor prognosis to allow prompt risk stratification and appropriate treatment. This study was performed to determine the clinical and prognostic characteristics in patients with syncope in APE.

Patients and methods
====================

We retrospectively reviewed the records of 179 consecutive patients with APE admitted to our pulmonary clinic at a tertiary university hospital between January 2013 and May 2015. The study was approved by the Ethics Review Board of Bulent Ecevit University and patient consent was not deemed necessary due to the retrospective nature of the study. APE diagnosis was established by computed tomography pulmonary angiography (CTPA; n=136), high probability ventilation/perfusion $(\overset{˙}{V}/\overset{˙}{Q})$ scan (n=41), and compression sonography of the leg veins with high clinical probability (n=2).

Syncope was defined as the sudden, temporary loss of consciousness with spontaneous recovery and without sequelae. The time from the onset of symptoms to hospital admission was defined as presentation time, and earlier presentation was classified as 24 hours or less. Cardiopulmonary disease was defined as the presence of one or more of the following conditions: chronic obstructive pulmonary disease, asthma, coal workers' pneumoconiosis, interstitial lung disease, and heart failure (ejection fraction ≤45% or clinically overt disease). Right ventricular (RV)-to-left ventricular diameter ratio \>1 on CTPA or pulmonary artery systolic pressure \>30 mmHg on echocardiography was defined as right ventricular dysfunction (RVD). Echocardiographic examination was performed within 5 days of presentation by a cardiologist. Thrombus localization on CTPA was classified as peripheral (isolated lobar, segmental, and/or subsegmental arteries) or central. The shock index was defined as the heart rate divided by systolic blood pressure. Troponin I and T were measured at different times (before and after June 2013, respectively). Therefore, statistical analysis was based on troponin positivity instead of continuous values. Troponin T levels were measured by electrochemiluminescence using the Elecsys e411 analyzer (Roche, Mannheim, Germany). Troponin I levels were measured by chemiluminescence using the Advia Centaur CP (Siemens, Munich, Germany).

Statistical analysis
====================

Descriptive statistics of the categorical variables are given as numbers or percentages; continuous variables are given as medians (min--max). The chi-square test or Fisher's exact test was used to evaluate categorical variables. The Mann--Whitney *U*-test was used to compare medians of variables.

Multivariate analysis was performed using logistic regression models with stepwise forward selection to identify independent predictors of syncope in patients with APE. All variables with a *P*-value \<0.20 in the initial analysis were included in multivariate analysis. The associations are presented as odds ratios (OR) with 95% confidence intervals (CI). Model discrimination was measured using the area under the receiver operating characteristic curve. Statistical analysis was performed using SPSS Version 18.0 for Windows (SPSS Inc., Chicago, IL, USA). All *P*-values were two-sided, and values less than 0.05 were considered statistically significant.

Results
=======

The prevalence of syncope at presentation was 13% in our study population. When age was treated as a dichotomous variable (\< and ≥60 years), a significant difference was observed between these two groups. The patients' clinical characteristics are listed in [Table 1](#t1-tcrm-12-1023){ref-type="table"}. No hemoptysis was seen in patients with syncope. In this study, angina-like pain and pleuritic pain were classified into the same category for chest pain. There was no significant difference between the two groups in terms of chest pain.

A conclusive diagnosis of PE was made by CTPA in 18 (78%) and by $\overset{˙}{V}/\overset{˙}{Q}$ scan in five (22%) patients with syncope. In patients with syncope, the thrombus was located centrally (*P*\<0.001). No bradycardia was recorded in patients with syncope. However, heart rate was \<70 bpm in 9% (2/23) of patients with syncope. Hemodynamic deterioration in patients who presented initially in a hemodynamically stable condition was considered an indication for thrombolytic treatment. The frequency of thrombolytic therapy was 17.4% in the group with syncope and 14.1% in the group without syncope, and the difference was not significant (*P*=0.751). All patients were given standard anticoagulant therapy, including intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin plus warfarin. The 30-day mortality rate was higher in patients with syncope than in the control group (13% vs 10%, respectively); however, the difference between the groups was not statistically significant.

Logistic regression analysis was performed to determine the independent factors associated with the presence of syncope in patients with APE. The following variables were entered into the multivariate analysis: age (\>60 years), earlier presentation, cardiopulmonary disease, diabetes, heart rate (\>120 bpm), respiratory rate (\>30/min), n (%) cardiac troponin (cTn) positivity, shock index, central localization, and RVD. Multivariate analysis showed that central localization (OR: 9.08) and cTn positivity (OR: 4.67) were independent correlates of the presence of syncope in patients with APE ([Table 2](#t2-tcrm-12-1023){ref-type="table"}). For the final regression model, the goodness of fit of the model was determined to be acceptable using the Hosmer--Lemeshow test (*P*=0.687), and the area under the curve was 0.807 (CI, 0.718--0.896) with *P*\<0.001.

Discussion
==========

The prevalence of syncope was 13% in our study group. This figure was identical to that reported in previous major studies.[@b4-tcrm-12-1023],[@b7-tcrm-12-1023],[@b13-tcrm-12-1023] A central location of the thrombus, troponin positivity, RVD, and increased heart and respiratory rates were more common in patients with syncope. Central thrombus location and troponin positivity were independent factors associated with the presence of syncope.

The classical triad of symptoms of APE includes dyspnea, hemoptysis, and pleuritic chest pain, but many patients are also asymptomatic or have an atypical presentation (syncope, abdominal pain, new onset cardiac arrhythmia, seizure, etc).[@b14-tcrm-12-1023]--[@b16-tcrm-12-1023] The diagnosis of APE continues to be difficult due to variability in the clinical picture among patients. It can be difficult to establish the clinical correlation when syncope is the presenting symptom of APE. Syncope seems to be related to central and/or massive APE.[@b4-tcrm-12-1023],[@b5-tcrm-12-1023] If syncope is associated with complete occlusion of the pulmonary blood flow, it progresses to cardiac arrest and death. However, in other cases, syncope is brief and is associated with transient hypotension because occlusion in central pulmonary arteries undergoes partial resolution. This situation results in survival of the patient, and at the same time, it obscures the diagnosis since the blood pressure may have stabilized.[@b4-tcrm-12-1023] Therefore, it is also interpreted as "forgotten sign" of life-threatening pulmonary embolism.[@b8-tcrm-12-1023]

The three major pathophysiological mechanisms proposed for the development of syncope in APE are acute right heart failure, hemodynamically unstable dysrhythmia (such as bradycardia or tachycardia), and vasovagal reflex. First, occlusion of \>50% of the pulmonary vascular bed can cause acute RV failure, impaired left ventricular filling, tachycardia, hypotension, and reduced cerebral perfusion. This seems to be the main mechanism responsible for the development of syncope in our study population. With regard to the other mechanisms, there was no electrocardiographic evidence regarding dysrhythmia on presentation. Of course, immediate electrocardiographic, hemodynamic, and echocardiographic examinations after syncope were not possible. The elapsed time between presentation and a syncopal episode may have been responsible for this condition. On the other hand, it should be kept in mind that dysrhythmias may also be the result of APE rather than the primary cause of syncope. None of our patients had a heart rate \<60 bpm or \>150 bpm. However, relative bradycardia (\<70 bpm) was observed in two of 23 patients (9%).

Upon appraisal of the symptoms, there was no difference between the groups in terms of dyspnea. Interestingly, none of the patients with syncope had hemoptysis. Duplyakov et al[@b17-tcrm-12-1023] reported similar observations. This condition may result from pulmonary hemorrhage/infarction syndrome associated with minor embolisms occluding the peripheral pulmonary arteries.[@b18-tcrm-12-1023] There was no difference between the groups in terms of chest pain, and so it was probably due to the classification of angina-like pain and pleuritic pain into a single category for chest pain.

In daily practice, cTnT and cTn I assays are used to diagnose acute coronary syndrome. However, elevated plasma cTnT or cTn I levels can also be observed as the result of transient ischemic or inflammatory myocardial injury in diseases such as pulmonary embolism, severe pulmonary hypertension, heart failure, myocarditis, cardiomyopathies, tachyarrhythmias, renal failure, and sepsis.[@b19-tcrm-12-1023] In APE, elevated cTn concentrations are a result of RV ischemia secondary to increased RV wall tension and neurohumoral activation and are associated with increased mortality.[@b20-tcrm-12-1023] In our study, subjects with syncope had a significantly higher rate of cTn positivity, indicating RV dysfunction.

Syncope in APE patients has generally been considered as an indicator of poor prognosis and has been used as a criterion for thrombolysis in some studies.[@b20-tcrm-12-1023]--[@b24-tcrm-12-1023] The circulatory collapse in APE was defined by the presence of shock or syncope (loss of consciousness) in the PIOPED study.[@b2-tcrm-12-1023],[@b25-tcrm-12-1023] Thames et al[@b4-tcrm-12-1023] demonstrated significant differences with regard to the pulmonary artery obstruction score (\>50%) and hemodynamic instability in APE patients with syncope. Konstantinides et al[@b26-tcrm-12-1023] showed that the 30-day mortality rate was significantly different between patients with and without syncope in APE (14. 4% vs 7. 8%, respectively, *P*=0.012).[@b26-tcrm-12-1023] Similarly, Kumasaka et al[@b27-tcrm-12-1023] found that syncope in APE was associated with increased in-hospital mortality (OR: 3.03, *P*=0.01).[@b27-tcrm-12-1023] In the International Cooperative Pulmonary Embolism Registry, the 3-month mortality rate of patients with syncope was 26.8%, whereas the overall mortality rate was 17%.[@b5-tcrm-12-1023],[@b13-tcrm-12-1023]

However, several recent studies indicated that syncope is not related to mortality, but is related to hemodynamic instability,[@b9-tcrm-12-1023],[@b10-tcrm-12-1023],[@b17-tcrm-12-1023] central or saddle embolism,[@b9-tcrm-12-1023],[@b11-tcrm-12-1023],[@b17-tcrm-12-1023] RVD,[@b11-tcrm-12-1023],[@b12-tcrm-12-1023] and troponin positivity.[@b10-tcrm-12-1023] However, in these studies, the groups with and without syncope differed in age, use of thrombolytics, and comorbidities. Interestingly, Seyyedi et al[@b12-tcrm-12-1023] reported that syncope in APE is associated with a decreased risk of mortality. The authors stated that these conflicting data may be due to the earlier diagnosis in patients with syncope. In this study, heart failure data were not reported, and RVD (94.7% vs 72.5%, respectively, *P*=0.003), central embolism (94.4% vs 86.0%, respectively, *P*=0.195), and saddle embolism (22.2% vs 11.5%, respectively, *P*=0.104) were more common in patients with syncope compared with the nonsyncope group.

Our results indicated that patients with syncope more commonly present with a centrally located thrombus, RVD, and troponin positivity. However, this condition was not associated with the 30-day mortality rate in our group. There could be several reasons for this observation. The patients with syncope were younger. It seems that age was the most important determinant of prognosis in our study group. In addition, they had less cases of cardiopulmonary disease (17% vs 33%) and a shorter duration from symptom onset to hospital admission (probably resulting in prompt treatment), although these differences were not statistically significant.

Limitations
-----------

This study had some limitations. The design of our study was retrospective. The small number of patients in the syncope group was another factor limiting the interpretation of the results. In addition, the definition of RVD was determined arbitrarily, because both diagnostic procedures (CTPA and echocardiography) were not performed in all patients. Our laboratory switched from measuring troponin I to troponin T during the study; however, previous reports have shown that both troponins have a similar ability to predict the prognoses of APE patients.[@b28-tcrm-12-1023]

Conclusion
==========

Syncope most likely represents an intermediate condition between massive APE and hypotension. The prognosis seems to depend on the underlying pathology, the patient's age, comorbidities, the duration from symptom onset to hospital admission, and the use of thrombolytic therapy.[@b5-tcrm-12-1023] In this study, the lack of differences in mortality rate does not eliminate the need for clinicians to remain alert in the management of patients with syncope.
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###### 

A comparison of presenting characteristics of patients with acute pulmonary embolism with and without syncope

  Variables                                                           All           Without syncope   With syncope   *P*-value
  ------------------------------------------------------------------- ------------- ----------------- -------------- ----------------------------------------------------
  Demographics                                                                                                       
   Age (years)                                                        68 (22--96)   68 (22--96)       60 (35--82)    0.152
   Age (\>60 years), n (%)                                            115 (64)      105 (67)          10 (44)        0.026[\*](#tfn3-tcrm-12-1023){ref-type="table-fn"}
   Sex (male), n (%)                                                  91 (51)       78 (50)           13 (57)        0.559
   Earlier presentation, n (%)                                        67 (37)       55 (35)           12 (52)        0.118
   Cardiopulmonary disease, n (%)                                     55 (31)       51 (33)           4 (17)         0.138
   Malignancy, n (%)                                                  23 (13)       19 (12)           4 (17)         0.486
   Diabetes mellitus, n (%)                                           51 (29)       42 (27)           9 (39)         0.226
   Hypertension, n (%)                                                104 (58)      91 (58)           13 (57)        0.869
  Symptoms, n (%)                                                                                                    
   Dyspnea                                                            150 (84)      132 (85)          18 (78)        0.440
   Chest pain                                                         102 (57)      89 (57)           13 (57)        0.962
   Hemoptysis                                                         18 (10)       18 (12)           0 (0)          0.134
   Cough                                                              41 (23)       37 (24)           4 (17)         0.500
  Physical examination, n (%)                                                                                        
   Heart rate (\>120 bpm)                                             32 (18)       24 (15)           8 (35)         0.023[\*](#tfn3-tcrm-12-1023){ref-type="table-fn"}
   SBP (\<90 mmHg)                                                    4 (2)         3 (2)             1 (4)          0.426
   RR (\>30/min)                                                      13 (8)        8 (5)             5 (26)         0.008[\*](#tfn3-tcrm-12-1023){ref-type="table-fn"}
  Laboratory, n (%)                                                                                                  
   cTn positivity[a](#tfn1-tcrm-12-1023){ref-type="table-fn"}         64 (45)       48 (39)           16 (80)        0.001[\*](#tfn3-tcrm-12-1023){ref-type="table-fn"}
   Shock index                                                        28 (16)       21 (14)           7 (30)         0.059
   Central localization[b](#tfn2-tcrm-12-1023){ref-type="table-fn"}   66 (49)       51 (43)           15 (83)        0.002[\*](#tfn3-tcrm-12-1023){ref-type="table-fn"}
   RVD                                                                127 (71)      106 (68)          21 (91)        0.021[\*](#tfn3-tcrm-12-1023){ref-type="table-fn"}
   30-day mortality                                                   19 (11)       16 (10)           3 (13)         0.716

**Notes:**

n=143,

n=136,

*P*\<0.05.

**Abbreviations:** SBP, systolic blood pressure; RR, respiratory rate; cTn, cardiac troponin; RVD, right ventricular dysfunction.

###### 

Multivariate analysis of factors associated with syncope

  Variables                 Unadjusted OR (95% CI)   *P*-value                                            Adjusted OR (95% CI)   *P*-value
  ------------------------- ------------------------ ---------------------------------------------------- ---------------------- ----------------------------------------------------
  Age (\>60 years)          0.37 (0.15--0.91)        0.030[\*](#tfn5-tcrm-12-1023){ref-type="table-fn"}                          
  Earlier presentation      0.50 (0.21--1.21)        0.122                                                                       
  Cardiopulmonary disease   0.43 (0.14--1.34)        0.147                                                                       
  Diabetes                  1.75 (0.70--4.33)        0.230                                                                       
  Heart rate (\>120 bpm)    2.93 (1.12--7.68)        0.028[\*](#tfn5-tcrm-12-1023){ref-type="table-fn"}                          
  RR (\>30/min)             6.30 (1.81--21.86)       0.004[\*](#tfn5-tcrm-12-1023){ref-type="table-fn"}                          
  cTn positivity            6.25 (1.97--19.82)       0.002[\*](#tfn5-tcrm-12-1023){ref-type="table-fn"}   4.67 (0.93--23.47)     0.061
  Shock index               2.81 (1.04--7.65)        0.043[\*](#tfn5-tcrm-12-1023){ref-type="table-fn"}                          
  Central localization      24.67 (3.15--191.24)     0.002[\*](#tfn5-tcrm-12-1023){ref-type="table-fn"}   9.08 (1.09--76.04)     0.042[\*](#tfn5-tcrm-12-1023){ref-type="table-fn"}
  RVD                       4.95 (1.12--21.95)       0.035[\*](#tfn5-tcrm-12-1023){ref-type="table-fn"}                          
  30-day mortality          1.31 (0.35--4.91)        0.686                                                                       

**Note:**

*P*\<0.05.

**Abbreviations:** OR, odds ratio; CI, confidence interval; RR, respiratory rate; cTn, cardiac troponin; RVD, right ventricular dysfunction.
